ClinicalTrials.gg
RecruitingNCT05853094Updated May 19, 2023

Postoperative Effects of Different Enterostomy Approaches

An interventional study of Ileostomy and Transverse colostomy in Colorectal Cancer, Colorectal Neoplasms Malignant and Intestinal Neoplasms, Malignant, sponsored by Fudan University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-19.

Sponsored by Fudan University · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by May 2026, 6 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 127 studies in Colorectal Neoplasms by Fudan University — 68 open to participants now, 72 under way, 8 of them phase 3. Colorectal Neoplasms · Fudan University.

Planned enrollment
21st of 97
300 · median 100
Started
2023
with 16 others
No phase
13 of 127
8 open now
Primary completion
2026-05
later than 30 of 71 live
Registered
72nd of 127
by date

Among the 127 studies in Colorectal Neoplasms by Fudan University, this one is the 21st largest by planned enrollment of the 97 interventional ones that give a count, is one of 17 that started in 2023, is one of 13 with no phase, reaches primary completion later than 30 of the 71 other live ones, and was the 72nd registered.

Colorectal Neoplasms

6,556 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

68 of the 127 studies in Colorectal Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:

63 more — sign in →

By country, each count listing its studies:

All 68 open studies →

Where they have run

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 127 studies in Colorectal Neoplasms by Fudan University, or all of them as a file.
02

Study summary

Exploring the effect of protective ileostomy compared with transverse colostomy on the occurrence of complications, the occurrence of serious side effects of adjuvant chemotherapy and disease recurrence in patients with low rectal cancer after radical surgery from the perspective of intestinal microecology.

Read the detailed description

Low rectum refers to the rectal area \<7 cm from the anal verge. At present, with the development of modern medical technology and the change of surgical concept, more and more patients can achieve the goal of radical treatment of low rectal cancer while preserving the anus. The occurrence of anastomotic leakage after anus-preserving surgery for low-grade rectal cancer is a more common and serious complication, with an incidence ranging from 2.4% to 15.9%, and the morbidity and mortality rate after anastomotic leakage can be as high as 16%.

A protective stoma protects the anastomosis by temporarily establishing an artificial channel above the anastomosis to divert feces and avoid mechanical pressure and contamination of the anastomosis by intestinal contents, allowing the anastomosis to grow and heal in relatively clean external conditions. The current choices of protective stoma sites are terminal ileum and transverse colon. Analysis of domestic and international studies shows that both protective transverse colostomy and ileostomy can achieve the effect of diversion of stool, but whether there is a difference in preventing anastomotic leakage and reducing adverse outcomes of anastomotic leakage remains to be investigated. There are significant inconsistencies between domestic and international studies regarding the incidence of stoma-related complications caused by different stoma sites: the study by Rondelli et al. showed that terminal ileostomy was associated with lower stoma-related complications, and a domestic meta-analysis recommended terminal ileostomy after radical rectal cancer surgery. In contrast, the study by the team from the Union Hospital showed that transverse colostomy was associated with significantly lower rates of stoma-related complications and perioperative complications of stoma reentry.

In addition, according to the Union Hospital team study, the incidence of postoperative intestinal microbiota dysbiosis was higher in patients who underwent ileostomy compared to those who underwent transverse colostomy. The total intestinal microbiota in the colon accounts for more than 90% of the systemic intestinal microbiota, and the intestinal microbiota in the large intestine can be roughly restored to preoperative levels after transverse colostomy, whereas a large amount of intestinal microbiota is lost and difficult to restore after ileostomy. The dominant flora in the colon, such as Clostridium and Enterococcus, are less likely to colonize the small intestine, which may adversely affect the intestinal and systemic immune regulation and antitumor immune effects of the body. In addition, patients with progressive low-grade rectal cancer routinely require adjuvant chemotherapy after radical surgery, and there are no studies at domestic or abroad on whether terminal ileostomy, which is more common than transverse colostomy for intestinal dysbiosis, has any differences on the efficacy and toxic side effects of adjuvant chemotherapy for patients; furthermore, it is also important to investigate whether the two different stoma methods have an impact on long-term disease recurrence and overall survival of patients. In addition, whether the two different stoma modalities have an effect on long-term disease recurrence and overall survival is also an important research question.

Therefore, the investigators propose to conduct a prospective, randomized, controlled study in patients with low-grade rectal cancer who underwent radical surgery (with or without neoadjuvant radiotherapy) to investigate whether there are differences in the incidence of complications, serious side effects of adjuvant chemotherapy, and disease recurrence after terminal ileostomy versus transverse colostomy from the perspective of intestinal microecology, and to explore the differences in systemic immunity, inflammatory, and metabolic status.

03

Conditions studied

  • Colorectal Cancer
  • Colorectal Neoplasms Malignant
  • Intestinal Neoplasms, Malignant

Keywords

  • Colorectal Cancer
  • Stoma
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pathological confirmed adenocarcinoma of the rectum;
  2. Patients age between 18-80;
  3. Baseline AJCC stage I-III: cT1-4N0-2M0 (AJCC-8 version);
  4. (ECOG) physical status score of 0 to 2;
  5. Patients voluntarily sign .

Exclusion criteria

Exclusion Criteria:

  1. Other types of rectal cancer (adenosquamous carcinoma, squamous carcinoma, neuroendocrine tumors, clear cell carcinoma, spindle cell carcinoma, undifferentiated carcinoma);
  2. Combination of rectal cancer with multiple carcinomas;
  3. Pre-operative presence of acute and chronic infectious diseases or foci of infection;
  4. Intraoperative radical surgery was not performed for various reasons;
  5. Colostomy was not performed at the same time as the radical rectal cancer surgery;
  6. Combined with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery;
  7. cancer;
  8. Serious heart, lung, liver and kidney disease, can not tolerate surgery;
  9. Active liver disease or abnormal liver function with , AST and more than 2 times the values;
  10. Renal impairment with Cr ≥ 2 times the upper limit of normal or BUN ≥ 2 times the upper limit of normal;
  11. Blood leukocytes below the lower limit of normal value, or below the lower limit of normal value, or with other blood system diseases;
  12. Pregnancy;
  13. Mental illness or serious intellectual disability who cannot describe their feelings correctly;
  14. Severe coagulation disorder, bleeding tendency;
  15. Patients with severe uncontrolled medical disease, recent history of myocardial infarction (within 3 months), uncontrolled severe hypertension and severe diabetes mellitus;
  16. Patients need to be on antibiotics/other probiotics for a long time.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
300 participants (estimated)

Study arms

  • Experimental
    Ileostomy

    Protective ileostomy as a defunction mean after low anterior resection

    Procedure: Ileostomy

  • Experimental
    Transverse colostomy

    Protective transverse colostomy as a defunction mean after low anterior resection

    Procedure: Transverse colostomy

Interventions

  • ProcedureIleostomy

    Protective loop ileostomy after low anterior resection

  • ProcedureTransverse colostomy

    Protective loop transverse colostomy after low anterior resection

06

What researchers measure

Primary outcomes

  1. Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing

    Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing

    Time frame: 1 month

  2. Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing

    Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing

    Time frame: 6 months

  3. Microbiome functional gene capacity in postoperative stoma pouch and distal intestine by metagenomic sequencing

    Determining the structural impact of different stoma methods on intestinal microecology by metagenomic sequencing

    Time frame: 3 years

Secondary outcomes

  1. Concentration of inflammatory markers

    Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT

    Time frame: 1 month

  2. Changes in cellular immunity status

    Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry

    Time frame: 1 month

  3. Changes in humoral immunity status

    Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry

    Time frame: 1 month

  4. Incidence of anastomotic leakage

    The occurrence of postoperative anastomotic leakage

    Time frame: 1 month

  5. Early postoperative complications rate

    Incidence of postoperative complications such as diarrhea, intestinal obstruction, incisional infection, stoma prolapse, stoma necrosis, parastomal hernia, irritant dermatitis, renal insufficiency, etc.

    Time frame: 1 month

  6. First intestinal gas time

    Documenting the patient's post-operative recovery

    Time frame: 1 month

  7. First defecation time

    Documenting the patient's post-operative recovery

    Time frame: 1 month

  8. Concentration of inflammatory markers

    Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT

    Time frame: 6 month

  9. Changes in cellular immunity status

    Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry

    Time frame: 6 month

  10. Changes in humoral immunity status

    Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry

    Time frame: 6 month

  11. Incidence of grade 3-4 serious side effects of adjuvant chemotherapy

    Assessed with Common Terminology Criteria for Adverse Events (CTCAE) v5.0

    Time frame: 6 month

  12. Adjuvant chemotherapy toxicity and quality of life scores

    Assessed with European Organization for Research and Treatment of Cancer high-dose chemotherapy specific quality of life questionnaire module (EORTC QLQ-HDC29), ranging from 29 to 116 and higher scores suggest worse quality of life

    Time frame: 6 months

  13. Concentration of inflammatory markers

    Measurement of plasma inflammatory markers such as IL-6, TNF-α, CRP and PCT

    Time frame: 3 years

  14. Changes in cellular immunity status

    Estimation of dynamics of cellular immunity as measured by the proportion of CD3+, CD4+, CD8+, CD4+CD25+CD127low, CD16+CD56+ cells using flowcytometry

    Time frame: 3 years

  15. Changes in humoral immunity status

    Estimation of dynamics of humoral immunity as measured by the proportion of CD3-CD19+, CD20+ cells using flowcytometry

    Time frame: 3 years

  16. Disease-free Survival

    Time between the start of surgical randomization and recurrence of disease or death (from any cause)Time between the start of surgical randomization and recurrence of disease or death (from any cause)

    Time frame: 3 years

  17. Overall Survival

    Time from the start of surgical randomization to death (from any cause)

    Time frame: 3 years

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2023; primary completion for May 2026, 35 months later.

Of 900 non-industry interventional studies with no phase under Colorectal Neoplasms, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 61. This study's planned 35 months is close to that.

Counting every sponsor, half of 958 studies reached it within 31 months; a quarter within 14 and three quarters within 60.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 10, 2023
First posted
May 10, 2023
StartEst.
Jun 23, 2023
Primary completionEst.
May 2026
CompletionEst.
May 2027
Last update
May 19, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05853094
Lead sponsor
Fudan University
Responsible party
Ma Yanlei (Chief Physician, Fudan University) — Principal investigator
First posted
May 10, 2023
Start date
Jun 23, 2023 (estimated)
Primary completion
May 2026 (estimated)
Completion
May 2027 (estimated)
Last update
May 19, 2023

Study contacts

Yanlei Ma, PhD
Contact
yanleima@fudan.edu.cn
(86)13122680635
Yichi Zhang, MD
Contact
22111230058@m.fudan.edu.cn
(86)18588731911
Yanlei Ma, PhD
principal investigator · Fudan University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion